Skip to main content
Sanofi logo

Sanofi — Investor Relations & Filings

Ticker · SAN ISIN · FR0000120578 LEI · 549300E9PC51EN656011 PA Manufacturing
Open in API
Filings indexed 4,405 across all filing types
Latest filing 2024-12-23 Regulatory Filings
Country FR France
Listing PA SAN

About Sanofi

https://www.sanofi.com/en/directory/

Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.

Recent filings

Filing Released Lang Actions
Communiqué de presse : Sanofi lance un programme de phase III pour son vaccin VPC21 et élargit sa collaboration avec SK Bioscience afin de développer une nouvelle génération de vaccins pneumococciques
Regulatory Filings Classification · 95% confidence The document is titled "Communiqué de presse" (Press Release) and announces a major business development: Sanofi launching a Phase III program for a vaccine candidate (VPC21) and expanding a collaboration with SK Bioscience regarding next-generation vaccines. It includes quotes from executives, details about the clinical trial expansion, financial terms of the agreement (upfront payment, milestones, royalties), and standard sections like 'About Sanofi' and 'Forward-Looking Statements'. This structure is characteristic of an official announcement intended for immediate public dissemination regarding significant corporate or operational news, rather than a formal regulatory filing like a 10-K, an earnings release (ER) which focuses strictly on financial figures, or a detailed Investor Presentation (IP). Since it is a press release announcing strategic business and clinical progress, it most closely aligns with a general corporate announcement. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a press release that doesn't fit the highly specific financial/governance categories, although 'RPA' (Report Publication Announcement) is sometimes used for announcements, this document is the substance of the news itself, not just an announcement *about* a report. However, in the context of financial databases, press releases detailing strategic updates often fall under a general announcement category. Since there is no specific 'Press Release' code, and this is a substantive announcement of strategic partnership and clinical trial progress, it is best classified as a general regulatory/corporate announcement, which maps best to RNS, or potentially ER if it contained key financial results, which it does not. Given the focus on partnership and clinical trial initiation, RNS (Regulatory Filings/General Announcement) is the best fit among the provided codes for a non-standard, non-financial-only announcement.
2024-12-23 French
Press Release: Sanofi initiates phase 3 program for PCV21 and expands collaboration with SK bioscience for next-generation pneumococcal conjugate vaccines
Regulatory Filings Classification · 95% confidence The document is explicitly titled and formatted as a "Press Release". It announces a significant business development: Sanofi initiating a Phase 3 program for PCV21 and expanding a collaboration with SK bioscience regarding vaccine development. This type of announcement, detailing strategic business moves, clinical trial progress, and financial terms of collaboration (upfront payments, milestones), is characteristic of a corporate news release. It is not a formal regulatory filing like a 10-K, a comprehensive quarterly report (IR), or a specific shareholder communication (DEF 14A). Since there is no specific category for a general 'Press Release' that isn't an earnings release (ER) or a specific transaction (TAR), and it is a substantive announcement rather than just a notice of publication (RPA), it fits best under the general 'Regulatory Filings' (RNS) category as a broad corporate announcement, although 'ER' might be considered if it contained quarterly results, which it does not. Given the content focuses on R&D and collaboration expansion, it is a significant corporate update, but RNS serves as the best fit among the provided options for a general, non-earnings press release.
2024-12-23 English
6-K
Regulatory Filings
2024-12-20 English
Communiqué de presse - Jean-Paul Kress rejoint le Conseil d’administration de Sanofi
Board/Management Information Classification · 100% confidence The document is a press release announcing a change in the company's Board of Directors: Jean-Paul Kress is joining the board as an independent director, replacing Gilles Schnepp. This directly corresponds to the definition of Board/Management Information, which covers announcements of changes in the company's board of directors or senior management.
2024-12-19 French
Presse release: Jean-Paul Kress to join Sanofi's Board of Directors
Board/Management Information Classification · 100% confidence The document is a press release announcing a change in the company's Board of Directors: Jean-Paul Kress joining and Gilles Schnepp leaving. This directly relates to the composition and membership of the governing body. According to the definitions, 'Board/Management Information (Code: MANG)' covers the 'Announcement of changes in the company's board of directors or senior management.' The content perfectly matches this description.
2024-12-19 English
Communiqué de presse : Les résultats positifs de phase IIb concernant le duvakitug illustrent son potentiel de meilleur médicament de sa catégorie pour le traitement de la colite ulcéreuse et de la ma
Earnings Release Classification · 99% confidence The document is a press release ("Communiqué de presse") dated December 17, 2024, announcing positive Phase IIb clinical trial results for a drug candidate (duvakitug) in treating Inflammatory Bowel Diseases (IBD). It details efficacy data, safety profiles, quotes from management, and outlines future plans (Phase III development). This content structure—announcing key results and future steps immediately following clinical trials—is characteristic of an Earnings Release (ER) or a general announcement related to business performance/developments. Since it is a formal announcement of key financial/operational results (clinical trial success), and not a full quarterly report (IR) or a transcript (CT), the most appropriate classification is Earnings Release (ER), as these often include significant operational milestones alongside financial highlights, or are used as the primary vehicle for such news. Given the focus on trial results and future development plans, it functions as a major operational update, fitting the ER category better than a general Regulatory Filing (RNS) or a specific Investor Presentation (IP). Q4 2024
2024-12-17 French

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.